A Study to Evaluate the Efficacy, Safety and Pharmacokinetics of CDI-988 in Healthy Adults After Challenge With Snow Mountain Virus
← catalyst calendarNCT07198139 · readout in 42 d
Sponsored by Cocrystal Pharma, Inc. (industry) · COCP — their whole pipeline →.
Phase
Phase 1/2
Status
Recruiting
Study type
Interventional
Design
Randomized · Quadruple · Treatment
Enrollment
40estimated
Sites
1
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2026-03-01 | estimated | When the study began enrolling |
| Primary completion | 2026-10-01 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2026-12-01 | estimated | The whole study's end, after follow-up |
| First posted | 2025-09-30 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-02-17 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Norovirus
Interventions
- Drug: CDI-988
- Drug: Placebo
- Other: Snow Mountain Virus
Primary outcome
what the primary-completion date above is the date OFIncidence of norovirus-confirmed disease
measured Day 0 to Day 21
Permalink · COCP's whole pipeline · Catalyst calendar · Every registered study · What changed